Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy

被引:41
|
作者
Palmieri, Beniamino [1 ]
Tremblay, Jacques P. [2 ,3 ]
Daniele, Lodi
机构
[1] Univ Modena & Reggio Emilia Med Sch, Dept Gen Surg & Surg Specialties, Surg Clin, I-41100 Modena, Italy
[2] Univ Laval, Dept Anat Physiol, Quebec City, PQ, Canada
[3] Univ Laval, Human Genet Unit, CHUQ Res Ctr, Quebec City, PQ, Canada
关键词
myoblasts; Duchenne muscular dystrophy; exon skipping; tacrolimus; cyclosporine; transplantation; PEDIATRIC LIVER-TRANSPLANTATION; MUSCLE PRECURSOR CELLS; LONG-TERM EVALUATION; MDX MICE; HOST MUSCLE; STEM-CELLS; IN-VIVO; SKELETAL-MUSCLE; SATELLITE CELLS; GENE-THERAPY;
D O I
10.1111/j.1399-3046.2010.01377.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
DMD is a genetic X-linked recessive disease that affects approximately one in 3500 male births. Boys with DMD have progressive and predictable muscle destruction because of the absence of Dys, a protein present under the muscle fiber membrane. Dys deficiency induces contraction-related membrane damages, activation of inflammatory-necrosis-fibrosis up to the cardiac-diaphragmatic failure and death. This review supports the therapeutic role of MT associated with immunosuppression in DMD patients, describing the history and the rationale of such approach. The authors underline the importance to evaluate a protocol of myoblast intradermal multi-injection to apply in young DMD patients.
引用
收藏
页码:813 / 819
页数:7
相关论文
共 50 条
  • [41] Advances in the treatment of Duchenne muscular dystrophy
    Ortez, Carlos
    Natera de Benito, Daniel
    Carrera Garcia, Laura
    Exposito, Jessica
    Nolasco, Gregorio
    Nascimento, Andres
    MEDICINA-BUENOS AIRES, 2019, 79 : 77 - 81
  • [42] Treatment options for Duchenne muscular dystrophy
    Emma Ciafaloni
    Richard T. Moxley
    Current Treatment Options in Neurology, 2008, 10 : 86 - 93
  • [43] Eteplirsen in the treatment of Duchenne muscular dystrophy
    Lim, Kenji Rowel Q.
    Maruyama, Rika
    Yokota, Toshifumi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 533 - 545
  • [44] Operative treatment in Duchenne muscular dystrophy
    Beck, M
    Naumann, T
    NERVENHEILKUNDE, 1999, 18 (05) : 257 - 259
  • [45] Effects of an Immunosuppressive Treatment in the GRMD Dog Model of Duchenne Muscular Dystrophy
    Barthelemy, Ines
    Uriarte, Ane
    Drougard, Carole
    Unterfinger, Yves
    Thibaud, Jean-Laurent
    Blot, Stephane
    PLOS ONE, 2012, 7 (11):
  • [46] Duchenne muscular dystrophy: genome editing gives new hope for treatment
    Crispi, Vassili
    Matsakas, Antonios
    POSTGRADUATE MEDICAL JOURNAL, 2018, 94 (1111) : 296 - 304
  • [47] Current and emerging treatment strategies for Duchenne muscular dystrophy
    Mah, Jean K.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 1795 - 1807
  • [48] THE POTENTIAL OF EXOSOMES FOR THE DIAGNOSIS AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    Galkin, I. I.
    Egorova, T., V
    BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY, 2019, (04): : 5 - 8
  • [49] Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy
    Eleonora S. D’Ambrosio
    Jerry R. Mendell
    Neurotherapeutics, 2023, 20 : 1669 - 1681
  • [50] The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy
    Guiraud, Simon
    Roblin, David
    Kay, Davies E.
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (03): : 179 - 192